| Humira (adalimumab) / AbbVie |
| Recruiting | 4 | 10 | | | Senior doctor Claus Zachariae, Abbott Denmark, Aage Bang Foundation | Urticaria | | | | |
| Ongoing | 4 | 315 | Europe | Methotrexate, Sulfasalazine, Leflunomide, Humira, N/A, Tablet, Injection, Methotrexate, Salazopyrin EN, Arava, Humira | University of Oxford, NIHR | Physical Inactivity , Poor dietary behaviour , Obesity , Overweight | | | | |
NCT00649922: Assessment of the Effect of Adalimumab on Response to Influenza Virus and Pneumococcal Vaccines in Subjects With Rheumatoid Arthritis |
|
|
| Completed | 4 | 226 | US | adalimumab, ABT-D2E7, Humira, placebo | Abbott | Rheumatoid Arthritis | 12/04 | 02/05 | | |
2006-001608-35: TREATMENT OF SCIATICA BY ADALIMUMAB INJECTION : A RANDOMIZED, DOUBLE BLIND CONTROLLED TRIAL. |
|
|
| Completed | 4 | 50 | Europe | HUMIRA, Solution for injection | Dr. Valérie gangji | To determine the efficacy of adalimumab in disc herniation-induced sciatica in a controlled randomised double blind pilot study. | | | | |
| Completed | 4 | 14 | Europe | Adalimumab, Humira | Skane University Hospital, Abbott, The Swedish Research Council, The Swedish Rheumatism Ass, Crafoord Foundation | Rheumatoid Arthritis | 02/07 | 02/07 | | |
NCT00291915: Multicenter Randomized Prospective Trial Comparing Methotrexate Alone or in Combination With Adalimumab in Early Arthritis |
|
|
| Unknown status | 4 | 80 | Europe | Adalimumab, Methotrexate | Goupe d'Etudes et de Recherche Clinique En Rhumatologie | Rheumatoid Arthritis, Arthritis | | 03/07 | | |
NCT00133315: TNFalfa Blocking Treatment of Spondylarthropathies |
|
|
| Completed | 4 | 50 | Europe | Infliximab, Etanercept, Adalimumab | Hvidovre University Hospital | Spondylarthropathies, Ankylosing Spondylitis, Psoriatic Arthritis | | 04/07 | | |
NCT00233558: Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid Arthritis |
|
|
| Terminated | 4 | 160 | US | adalimumab (up to 9 months exposure), methotrexate | Abbott | Rheumatoid Arthritis | | | | |
| Completed | 4 | 52 | Europe | Adalimumab (Humira), Humira | Hvidovre University Hospital, Abbott | Rheumatoid Arthritis, Arthritis, Joint Diseases | 07/07 | 07/07 | | |
|
| Completed | 4 | 1938 | US | adalimumab | Abbott | Rheumatoid Arthritis | | | | |
VIVIR, NCT00761514: Evaluation of Quality of Life Changes in Puerto Rican Subjects With Active Rheumatoid Arthritis Treated With Humira |
|
|
| Terminated | 4 | 14 | US | Humira (adalimumab), ABT-D2E7, adalimumab, Humira | Abbott | Rheumatoid Arthritis | 08/08 | 08/08 | | |
NCT00234234: Predictors of the Response to Adalimumab in Rheumatoid Arthritis |
|
|
| Completed | 4 | 200 | Europe | Adalimumab | University Hospital, Rouen | Rheumatoid Arthritis | 12/08 | 12/08 | | |
NCT00216177: Comparison of Adalimumab and Infliximab Treatment of Rheumatoid Arthritis |
|
|
| Unknown status | 4 | 112 | Europe | Infliximab, remicade, Adalimumab, Humira | Hvidovre University Hospital, University Hospital, Gentofte, Copenhagen | Rheumatoid Arthritis | 01/09 | 06/09 | | |
| Unknown status | 4 | 52 | Europe | Adalimumab, Placebo | Glostrup University Hospital, Copenhagen, Abbott | Spondyloarthritis | 01/09 | 01/13 | | |
|
NCT00735787: Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet |
|
|
| Completed | 4 | 81 | US, Canada | Placebo, Adalimumab, Humira, ABT-D2E7 | Abbott | Psoriasis | 09/09 | 09/09 | | |
| Completed | 4 | 203 | US, Canada, Europe, RoW | Infliximab | Centocor Ortho Biotech Services, L.L.C., Schering-Plough | Rheumatoid Arthritis | 01/10 | 06/10 | | |
NCT00972218: Effectiveness and Safety of Spondylitis Related to Inflammatory Bowel Disease |
|
|
| Withdrawn | 4 | 0 | Canada | Adalimumab, Humira | University of Alberta, Abbott | Spondyloarthritis, Crohn's Disease | 01/10 | 01/10 | | |
NCT00833729: The Safety & Efficacy of Etanercept in Psoriasis Patients Who Have Not Responded to Adalimumab |
|
|
| Completed | 4 | 10 | Canada | etanercept | Dermatrials Research, Amgen | Plaque Psoriasis | 02/10 | 02/10 | | |
| Completed | 4 | 1032 | US, Canada, Europe, RoW | adalimumab, Humira, D2E7, methotrexate, placebo | Abbott | Rheumatoid Arthritis | 07/10 | 07/10 | | |
|
|
NCT00796705: Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA) |
|
|
| Terminated | 4 | 13 | US | Adalimumab, Humira, Adalimumab placebo, Humira placebo, Etanercept, Enbrel | National Institute of Allergy and Infectious Diseases (NIAID) | Rheumatoid Arthritis | 10/10 | 10/10 | | |
ELIDACE, NCT01237262: Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After TNF Alfa Inhibitors Therapy |
|
|
| Unknown status | 4 | 20 | Europe | Adalimumab, etanercept, infliximab | University of Padova | Moderate to Severe Psoriasis., Absolute Number, Density of Immune Infiltrate and Dendritic Cells and Inflammatory Cytokines Expression Pattern. | 11/10 | | | |
NCT01072058: Heart Function in Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker |
|
|
| Unknown status | 4 | 100 | RoW | TNF blockers (infliximab, adalimumab, etanercept) | University of Sao Paulo | Arthritis, Rheumatoid, Spondylitis, Ankylosing | 02/11 | | | |
|
| Completed | 4 | 42 | Europe | Adalimumab, Humira | Glostrup University Hospital, Copenhagen, University Hospital, Gentofte, Copenhagen, Copenhagen University Hospital at Herlev, Copenhagen University Hospital, Hvidovre | Psoriatic Arthritis | 06/11 | 06/11 | | |
|
NCT00940862: Effect of Adalimumab on Vascular Inflammation in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Completed | 4 | 30 | Canada | adalimumab, Humira, UVB Phototherapy, Ultra violet light B, Topical treatment | Innovaderm Research Inc., Abbott, Montreal Heart Institute | Psoriasis, Vascular Inflammation, Coronary Atherosclerosis | 06/11 | 08/11 | | |
NCT01181570: Efficacy and Safety of Adalimumab in Patients With Psoriasis and Obstructive Sleep Apnea |
|
|
| Completed | 4 | 20 | Canada | Adalimumab, Humira, mannitol, citric acid monohydrate, sodium citrate, disodium phosphate dihydrate, sodium dihydrogen phosphate dihydrate, sodium chloride, polysorbate 80, water for injection, sodium hydroxide., Placebo, sodium hydroxide | Innovaderm Research Inc., Abbott | Psoriasis, Sleep Apnea, Obstructive | 08/11 | 09/11 | | |
| Completed | 4 | 33 | US | Methotrexate, Methotrexate (MTX), Folic Acid, Adalimumab (Humira), Humira | Tufts Medical Center | Psoriasis | 12/11 | 05/17 | | |
NCT01265823: Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Completed | 4 | 150 | RoW | Adalimumab, ABT-D2E7, Humira | AbbVie (prior sponsor, Abbott) | Psoriasis | 02/12 | 02/12 | | |
2007-005464-26: Devlopment of Heart and blood vessel problems in patients with conditions which cause long-term, widespread, inflammation in the body. |
|
|
| Completed | 4 | 100 | Europe | Cimzia, Powder for concentrate for solution for infusion, Solution for injection, Remicade, Enbrel, Humira, Cimzia | Kings College London, Guys and St Thomas'NHS Foundation Trust, Guy's and St Thomas' NHS Foundation Trust BRC | Rheumatoid Arthritis, Chronic inflammation due to a defective autoimmume response, Diseases [C] - Immune System Diseases [C20] | | | | |
| Terminated | 4 | 7 | Europe | Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity (etanercept or adalimumab) | Glostrup University Hospital, Copenhagen | SPONDYLOARTHRITIS | 05/12 | 05/12 | | |
NCT01283971 / 2010-023587-40: A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor |
|
|
| Terminated | 4 | 96 | US, Europe, RoW | tocilizumab [RoActemra/Actemra], RoActemra/Actemra, adalimumab, placebo to tocilizumab, placebo to adalimumab, methotrexate, folate | Hoffmann-La Roche | Rheumatoid Arthritis | 08/12 | 08/12 | | |
| Completed | 4 | 33 | Europe | adalimumab, ABT-D2E7, HUMIRA, methotrexate | AbbVie (prior sponsor, Abbott), Pharma Consulting Group AB | Arthritis, Rheumatoid | 09/12 | 09/12 | | |
NCT01405326: REstore Working Ability in RheumatoiD Arthritis |
|
|
| Unknown status | 4 | 160 | Europe | adalimumab, Humira | The Rheumatological Center of Helsinki, Abbott | Rheumatoid Arthritis | 12/12 | 03/13 | | |
MUSICA, NCT01185288: A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab |
|
|
| Completed | 4 | 309 | US | Adalimumab, ABT-D2E7, Humira, Methotrexate | AbbVie (prior sponsor, Abbott) | Rheumatoid Arthritis | 01/13 | 01/13 | | |
|
|
| Unknown status | 4 | 66 | Europe | Adalimumab treatment arm, Humira, Adalimumab, Fumaric acid esters treatment group, Fumaderm, Narrow band UVB radiation | Medical University of Vienna | Psoriasis, Cardiovascular Diseases, Diabetes Mellitus, Type 2 | 05/13 | 05/14 | | |
2012-005809-53: What is the biologic drug concentration required to maintain stable disease activity in psoriasis? |
|
|
| Ongoing | 4 | 65 | Europe | adalimumab, etanercept, Ustekinumab, Solution for injection, Humira, Enbrel, Stelera | | Psoriasis, Psoriasis, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] | | | | |
| Completed | 4 | 30 | Europe | Adalimumab, Humira | Regionshospitalet Silkeborg, Abbott, Medtronic - MITG, Central Denmark Region | Spondyloarthritis, Enterocolitis | 06/13 | 03/14 | | |
NCT01505855: Efficacy Study of Pneumococcal Vaccination in Crohn's Disease |
|
|
| Completed | 4 | 197 | RoW | 23-valent polysaccharide pneumococcal vaccine, Pneumovax | Kyunghee University Medical Center, Wonju Severance Christian Hospital, Seoul National University Hospital, Asan Medical Center, Soonchunhyang University Hospital, Ewha Womans University, Kosin University Gospel Hospital, Chung-Ang University Hosptial, Chung-Ang University College of Medicine, Inje University, The Catholic University of Korea, Keimyung University Dongsan Medical Center, Korea University, Wonkwang University, Severance Hospital, Konkuk University Hospital | Crohn's Disease | 06/13 | 06/13 | | |
2012-004940-31: Investigation of the molecular size distribution of hyaluronan and the effect of adalimumab treatment of psoriatic arthritis. |
|
|
| Ongoing | 4 | 30 | Europe | Injection, Humira | Dept of medical sciences, Rheumatology, AbbVie | Active psoriatic arthritis according to CASPAR, Psoriatic arthritis is a painful joint condition connected to psoriasis., Diseases [C] - Immune System Diseases [C20] | | | | |
| Completed | 4 | 69 | Europe | adalimumab, Humira | University Hospital, Tours | Rheumatoid Arthritis | 07/13 | 07/13 | | |
2012-004939-23: Effet de la COmbinaison de Méthotrexate et d’Adalimumab sur la Réduction de l’Immunisation au cours de la Spondylarthrite ankylosante Effet de la COmbinaison de Méthotrexate et d’Adalimumab sur la Réduction de l’Immunisation au cours de la Spondylarthrite ankylosante |
|
|
| Ongoing | 4 | 110 | Europe | Solution for injection/infusion in pre-filled syringe, METOJECT | CHRU de TOURS, CHRU de TOURS | Cette étude portera sur une population avec une spondylarthrite ankylosante (SA) active nécessitant un traitement par adalimumab Cette étude portera sur une population avec une spondylarthrite ankylosante (SA) active nécessitant un traitement par adalimumab, Spondylarthrite ankylosante (SA) Spondylarthrite ankylosante (SA), Body processes [G] - Immune system processes [G12] | | | | |
| Completed | 4 | 300 | Europe, RoW | infliximab, etanercept, adalimumab, abatacept, rituximab or tocilizumab | University Hospital, Strasbourg, France | Rheumatoid Arthritis | 08/13 | 08/13 | | |
|
NCT01644396: An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation |
|
|
| Completed | 4 | 50 | RoW | Adalimumab, ABT-D2E7, Humira | AbbVie (prior sponsor, Abbott) | Moderate to Severe Plaque Psoriasis | 09/13 | 09/13 | | |
NCT00837434: Anti-TNF Agents for the Treatment of Rheumatoid Arthritis |
|
|
| Completed | 4 | 63 | US | Etanercept, Enbrel®, Adalimumab, Humira®) | National Institute of Allergy and Infectious Diseases (NIAID), Autoimmunity Centers of Excellence, Rho Federal Systems Division, Inc. | Rheumatoid Arthritis | 11/13 | 01/14 | | |
ASIM, NCT01029847: Adalimumab in Axial Spondyloarthritis () - MRI and Biomarkers in Patients With Spondyloarthritis |
|
|
| Completed | 4 | 49 | Europe | Adalimumab, Placebo | Rigshospitalet, Denmark | Spondyloarthritis | 12/13 | 12/13 | | |
2012-003736-23: A randomised controlled trial to compare withdrawal of therapy versus continuing therapy in low disease states in psoriatic arthritis – feasibility study |
|
|
| Completed | 4 | 30 | Europe | methotrexate po, salazopyrin EN, leflunomide, cyclosporin, etanercept, infliximab, adalimumab, methotrexate s/c, golimumab, Tablet, Capsule, soft, Solution for injection, Powder for solution for infusion, , Methotrexate, Salazopyrin En-Tabs, arava, neoral, enbrel, Remicade, Humira, Simponi | University of Leeds, Arthritis Research UK | psoriatic arthritis, psoriatic arthritis, Diseases [C] - Musculoskeletal Diseases [C05] | | 12/13 | | |
NCT01270035: Efficacy and Safety of Adalimumab 80 mg Every Other Week With Methotrexate |
|
|
| Unknown status | 4 | 40 | Japan | Adalimumab | Keio University, Saitama Medical University | Rheumatoid Arthritis | 01/14 | | | |
2013-003956-18: Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis (JIA) Preventie van recidieven door risico-aangepast staken van de behandeling bij juveniele idiopathische artritis (JIA) |
|
|
| Ongoing | 4 | 325 | Europe | enbrel, humira, orencia, methotrexate, Methotrexate, EU/1/99/126/001, EU/1/03/256/001, EU/1/07/389/001, RVG 28636, RVG 104433, Injection, Infusion, Tablet, enbrel, humira, orencia, methotrexate | University Medical Center Utrecht, Interdisziplinäre Zentrum für Klinische Forschung Münster | juvenile idiopathic arthritis juveniele idiopathische artritis, juvenile (rheumatoid) arthritis jeugdreuma, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
NCT02132234: Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis |
|
|
| Unknown status | 4 | 100 | Europe | Etanercept, Adalimumab, Certolizumab, Infliximab | Jagiellonian University, Departmet of Rheumatology, J Dietl Hospital, Krakow, Poland | Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Hypertension | 07/14 | | | |
2010-020738-24: To see whether for patients with established rheumatoid arthritis that have already achieved a good response to Tumour Necrosis Factor Inhibitor (TNF inhibitor) treatment, whether the treatment be tapered to a minimum dose without affecting the control of disease activity. |
|
|
| Completed | 4 | 99 | Europe | Etanercept, Adalimumab, Solution for injection, Enbrel pre-filled pen, Humira, Enbrel pre-filled syringe | King's College London | Patients with established Rheumatoid arthritis, An inflammatory disorder which affects tissues and organs, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2009-014348-12: Helkrops MR, MR af sacroiliacaled og columna totalis og cirkulerende biomarkører hos patienter med spondylartritis i behandling med adalimumab (ASIM) |
|
|
| Completed | 4 | 50 | Europe | Humira, Adalimumab, Injection*, Humira | Mikkel Østergaard | Spondyloartritis | | 08/14 | | |
2014-001919-39: Increasing the time between adalimumab injections from two to three weeks, in patients with inflammatory bowel disease. |
|
|
| Ongoing | 4 | 80 | Europe | adalimumab, Solution for injection in pre-filled pen, Humira | Erasmus MC, Erasmus MC, fonds NutsOhra | Inflammatory bowel disease, Inflammatory bowel disease, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT00517296: Endoscopic Ultrasound (EUS) Guided Treatment With Humira for Crohn's Perianal Fistulas |
|
|
| Completed | 4 | 21 | US | EUA with seton placement if necessary, adalimumab, EUS | Vanderbilt University Medical Center | Crohn Disease, Rectal Fistula | 12/14 | 12/15 | | |
| Completed | 4 | 302 | Europe | etanercept or adalimumab, Enbrel, Humira, Rituximab, MabThera | University of Glasgow, Arthritis Research UK, NHS Lothian, NHS Grampian, NHS Tayside, NHS Borders, NHS Fife | Rheumatoid Arthritis | 12/14 | 04/15 | | |
| Completed | 4 | 120 | Europe | Reduced doses of anti-TNF, Adalimumab: 40 mg / 3 weeks, Etanercept: 50 mg / 10 days, Golimumab: 50 mg / 6 weeks, Infliximab: 3 mg/kg / 8 weeks, Stable doses of anti-TNF, Adalimumab: 40 mg / 2 weeks, Etanercept: 25 mg / 3 days ó 50 mg /7 days, Golimumab: 50 mg / 4 weeks, Infliximab: 5 mg/kg / 6-8 weeks | Spanish Clinical Pharmacology Society, Spanish reumatology Society | Spondylarthropathies | 04/15 | 09/15 | | |
| Completed | 4 | 110 | Europe | Adalimumab, Humira, Methotrexate, Metoject | University Hospital, Tours, CHRU de TOURS | Ankylosing Spondylitis | 04/15 | 04/15 | | |
NCT01960426: Evaluation of Health Costs and Resource Utilization |
|
|
| Terminated | 4 | 51 | US | Measurement of drug (Adalimumab/Infliximab), Intensify treatment with the existing drug | University of Western Ontario, Canada, Prometheus Laboratories | Ulcerative Colitis, Crohn's Disease | 05/15 | 05/15 | | |
NCT01543204: Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab |
|
|
| Terminated | 4 | 64 | US, Canada | Etanercept, Enbrel® | Amgen | Psoriasis | 05/15 | 05/15 | | |
ROCKIES, NCT01927757: Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab |
|
|
| Terminated | 4 | 90 | US, Canada | Etanercept, Enbrel®, Methotrexate | Amgen | Moderate to Severe Rheumatoid Arthritis | 06/15 | 06/15 | | |
2014-005722-35: Measures of inflammation in low back pain and anti-TNFα (anti-inflammation treatment) for the treatment of deemed low back pain - an explorative study |
|
|
| Terminated | 4 | 40 | Europe | Humira, Solution for injection, Humira (adalinomap) | Glostrup University Hospital, IMK Almene Fond | Low back pain with and without legg-painIn the late periode 1990ies it became clear that various cytokines and other inflammatory elements played a large role for low back pain. One of the known inflammatory substances TNF-α (Tumor Necrosis Factor-α) has been demonstrated in the discs’ nuclear tissue, particular with degeneration., Low back pain In the late periode 1990ies it became clear that inflammation played a large role for low back pain. TNF-α treatment may be usefull., Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
RADAR, NCT01162421: A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid Arthritis |
|
|
| Completed | 4 | 77 | Canada | adalimumab, ABT-D2E7, Humira, Methotrexate, Trexall, Rheumatrex | AbbVie (prior sponsor, Abbott), Mount Sinai Hospital, Canada | Rheumatoid Arthritis | 07/15 | 07/15 | | |
2015-002284-42: The rationale for this study is to gain insight in the extent and impact of immunogenicity of TNF inhibitors in the European daily clinical practice. Furthermore, an European wide database will give insight in factors influencing immunogenicity and treatment outcome in terms of disease activit |
|
|
| Completed | 4 | 1650 | Europe | etanercept, adalimumab, certolizumab pegol, golimumab, infliximab, Injection, Infusion, Enbrel, Humira, Cimzia, Simponi, Remicade | READE, PFIZER | rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and psoriasis., rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and psoriasis., Not possible to specify | | | | |
2015-000863-15: RANDOMIZED CONTROLLED CLINICAL TRIAL EVALUATING METHOTREXATE + BIOLOGIC VERSUS METHOTREXATE, SALAZOPYRINE AND HYDROXYCHLOROQUINEIN PATIENTS WITH RHEUMATOID ARTHRITIS AND INSUFFICIENT RESPONSE TO METHOTREXATE |
|
|
| Not yet recruiting | 4 | 286 | Europe | L04AB01, Powder and solution for solution for injection, Solution for injection, Concentrate for solution for infusion, Solution for infusion, Concentrate for solution for injection, Tablet, Powder and solvent for solution for injection, ENBREL, HUMIRA, REMICADE, ORENCIA, SIMPONI, CIMZIA, ROACTEMRA, MABTHERA, SALAZOPYRINE, IMETH, METOJECT, PLAQUENIL | Hôpitaux Universitaires de Strasbourg, Ministry of Health | RHEUMATOID ARTHRITIS, PATIENTS WITH RHEUMATOID ARTHRITIS AND INSUFFICIENT RESPONSE TO METHOTREXATE, Diseases [C] - Immune System Diseases [C20] | | | | |
| Completed | 4 | 122 | Europe | Etanercept, Abatacept, Rituximab, Adalimumab, Certolizumab Pegol, Infliximab, Golimumab | Julia Brown | Rheumatoid Arthritis | 11/15 | 11/15 | | |
|
NCT01500278 / 2011-002067-20: Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate |
|
|
| Completed | 4 | 915 | Canada, US, Europe, RoW | Certolizumab Pegol (CZP), Cimzia, CZP, Adalimumab (ADA), Humira, ADA, Methotrexate (MTX), MTX | UCB Pharma SA, Parexel | Rheumatoid Arthritis | 11/15 | 01/16 | | |
|
|
|
NCT02489760: Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study |
|
|
| Unknown status | 4 | 30 | RoW | Adalimumab, Humira, Etanercept, Enbrel | Chung Shan Medical University | Ankylosing Spondylitis | 12/15 | 10/16 | | |
NCT01722214: Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis |
|
|
| Completed | 4 | 107 | Canada | Adalimumab, Humira, Placebo | Innovaderm Research Inc., Abbott, Montreal Heart Institute | Psoriasis, Vascular Inflammation, Coronary Atherosclerosis | 12/15 | 01/16 | | |
2005-001633-14: Randomised, multi-center, open-label, parallel-group study comparing adalimumab (Humira) 40 mg s.c. eow versus infliximab (Remicade) 3 mg/kg i.v. every 6. week in RA patients with unsustainable clinical response to infliximab 3 mg/kg every 8. week |
|
|
| Ongoing | 4 | 80 | Europe | Humira, Remicade, Humira, Remicade, Humira, Remicade | Hvidovre Hospital, Dept. Rheumatology | Rheumatoid arthritis | | | | |
2006-006275-21: A Randomised, Pragmatic, Open-label study of Adalimumab versus Etanercept for Rheumatoid Arthritis. |
|
|
| Ongoing | 4 | 124 | Europe | Humira, Enbrel, Humira, Enbrel | University Hospital Birmingham NHS Foundation Trust | Rheumatoid Arthritis | | | | |
2006-006632-22: Change from infliximab to adalimumab in patients with Crohn’s disease in remission on infliximab: a randomized comparative case control study. |
|
|
| Ongoing | 4 | 100 | Europe | HUMIRA, REMICADE, HUMIRA, REMICADE | University of Leuven, Division of Gastroenterology | Luminal Crohns Disease, moderate to severe, refractory to steroids and/or antimetabolitets and controlled with anti-TNF therapy | | | | |
2006-006186-16: IMPROVED: Induction therapy with Methotrexate and Prednisone in Rheumatoid Or Very Early arthritic DiseaseA randomized clinical trial in patients with recent-onset arthritis to compare the efficacy of DMARD combination therapy including prednisone with combination therapy including adalimumab, a TNF-blocking agent |
|
|
| Ongoing | 4 | 535 | Europe | Methotrexate, Prednisone, Sulfasalazine, hydroxychloroquine, adalimumab, MTX, HCQ, hydroxychloroquine, Humira, hydroxychloroquine, Humira | Leiden University Medical Center, department of rheumatology | rheumatoid arthritis and undifferentiated arthritis | | | | |
2006-004971-37: Adalimumab for psoriasis patients who are non-responders to etanercept: An open-label study |
|
|
| Terminated | 4 | 20 | Europe | Humira 40mg for injection in pre-filled syringe (adalimumab), NA, Solution for injection, Humira | King's College London, Guy's and St Thomas' NHS Foundation Trust | psoriasis | | | | |
2007-001190-28: Randomised controlled trial of tumour-necrosis-factor inhibitors against combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis |
|
|
| Ongoing | 4 | 190 | Europe | Methotrexate, Sulfasalazine, Hydroxychloroquine, Ciclosporin, Leflunomide, Sodium aurothiomalate (intramuscular gold), methylprednisolone, Prednisolone, Infliximab, Etanercept, Adalimumab, Azathioprine, Penicillamine, Methotrexate, Sulfasalazine, Hydroxychloroquine, Ciclosporin, Leflunomide, Sodium aurothiomalate (intramuscular gold), methylprednisolone, Prednisolone, Infliximab, Etanercept, Adalimumab, Azathioprine, Penicillamine, | King\'s College London | Rheumatoid Arthritis | | | | |
2007-000082-38: The OPERA Study. Optimized treatment algorithm in early rheumatoid arthritis: Methotrexate and intra-articular glucocorticosteroid plus adalimumab or placebo in the treatment of early rheumatoid arthritis. A Randomised, double-blind and placebo-controlled, two arms, parallel group study of the additive effect of adalimumab concerning inflammatory control and inhibition of erosive development. |
|
|
| Ongoing | 4 | 180 | Europe | Humira® (adalimumab), 2593, Humira (adalimumab), Humira (adalimumab) | Abbott A/S Laboratories , Denmark | In early RA methotrexate and intra-articular glucocorticoid in combination with adalimumab is better than methotrexate and intra-articular glucocorticoid in achieving control of the disease as assessed by DAS28 < 3.2. | | | | |
2007-000593-24: An Open-Label, Observational Study of the Effects of Anti-TNF Therapy on Peripheral Blood and Synovial Biomarkers in Patients with Active Rheumatoid Arthritis. |
|
|
| | 4 | 26 | Europe | Enbrel, Humira, Enbrel, Humira | F. Hoffmann-La Roche Ltd, F.Hoffmann-La Roche Ltd | Rheumatoid Arthritis. | | | | |
2008-004926-18: Comparison of the human TNF-alpha antibody adalimumab with infliximab in induction and maintenance of steroid-free remission in patients with moderate to severe Crohn’s disease |
|
|
| Ongoing | 4 | 100 | Europe | Humira, Remicade, Humira, Remicade | IBD Center LMU Munich | Moderate to severe Crohn’s disease | | | | |
2008-001952-32: The effect of adalimumab on immune markers in lesional psoriatic skin. |
|
|
| Ongoing | 4 | 10 | Europe | Humira, Humira | Radboud University Nijmegen Medical Centre - Department of Dermatology | Plaque psoriasis | | | | |
2009-011625-13: \"PSOGEN:Effect adalimumab op zelfbeeld en seksueel functioneren bij matige en ernstige psoriasis van de anogenitale regio; prospectief, open label pilot onderzoek\" |
|
|
| Ongoing | 4 | 20 | Europe | Humira, Humira, Humira | Abbott | Anogenital Psoriasis | | | | |
2008-005619-16: Impact of anti-tumor necrosis factors antibodies treatment on fertility of inflammatory bowel diseases male patients |
|
|
| Ongoing | 4 | 100 | Europe | infliximab, adalimumab, | Erasmus Medical Center | Fertility influenced by antiTNF treatment | | | | |
2008-005450-20: The cost-effectiveness of abatacept, rituximab or anti-TNF alpha for patients with rheumatoid artritis. |
|
|
| Ongoing | 4 | 33 | Europe | Remicade (infliximab), Humira (adalimumab), Enbrel (etanercept), Mabthera (rituximab), Orencia (abatacept), Remicade (infliximab), Humira (adalimumab), Enbrel (etanercept), Mabthera (rituximab), Orencia (abatacept) | Radboud University Nijmegen Medical Centre, department of Rheumatic Diseases | Rheumatoid arthritis | | | | |
2009-015099-86: Comparison of efficacy, safety and costs of outpatient biological treatment for psoriasis in daily clinical practice. |
|
|
| Ongoing | 4 | 200 | Europe | Humira, Enbrel, Humira, Enbrel | Radboud University Nijmegen Medical Centre | Psoriasis | | | | |
2009-017325-19: “The effect of Six months Adalimumab Treatment on Sick Leaves and retirement in Patients with rheumatoid Arthritis who are at risk of losing their ability to work” |
|
|
| Ongoing | 4 | 160 | Europe | HUMIRA, HUMIRA | Helsingin reumakeskus | Rheumatoid arthritis | | | | |
2010-018279-99: Skin Topoproteome under Adalimumab (Humira®) Treatmentin Patients with Moderate to Severe Psoriasis |
|
|
| Ongoing | 4 | 12 | Europe | Humira 40 mg injection solution in pre-filled syringe, Humira 40 mg injection solution in pre-filled syringe | Faculty of Medicine, Otto-von-Guericke-University Magdeburg | Disease under investigation: Adult patients of both genders with moderate to severe chronic plaque psoriasis who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVA. This is the exact label indication of Humira. Conditions: In this clinical trial Humira treatment will be performed completely \"in-label\" over 16 weeks (and facultatively over an additional 4 weeks during follow-up). | | | | |
| Completed | 4 | 10 | Europe | Humira, Humira | Overlæge, dr.med. Claus Zachariae | Kronisk urticaria | | | | |
2012-004482-40: Evaluation of a protocol for the reduction of doses in patients with rheumatoid arthritis (RA) in clinical remission in treatment with biological therapies Evaluación de un protocolo para la disminución de dosis en pacientes con Artritis Reumatoide (AR) en remisión clínica en tratamiento con terapias biológicas |
|
|
| Ongoing | 4 | 28 | Europe | Infliximab, Adalimumab, Etanercept, Certolizumab Pegol, Golimumab, Abatacept, Tocilizumab, Lyophilisate for solution for infusion, Solution for injection in pre-filled syringe, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, HUMIRA, ENBREL, CIMZIA, SIMPONI, ORENCIA, RoActemra | FRANCISCO J. BLANCO GARCÍA, FRANCISCO J. BLANCO GARCIA | Evaluation of the clinical utility of a standardized protocol of strategies for the reduction of doses in patients with rheumatoid arthritis in clinical remission at treatment with biologic therapies Evaluación de la utilidad clínica de un protocolo estandarizado de estrategias para la disminución de dosis en pacientes con Artritis Reumatoide en remisión clínica a tratamiento con terapias biológicas, Evaluation of a protocol for the reduction of doses in patients with rheumatoid arthritis in remission at treatment with biologic therapies Evaluación de un protocolo para la disminución de dosis en pacientes con Artritis Reumatoide en remisión a tratamiento con terapias biológicas, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2013-002932-25: A randomized clinical trial: treatment of perianal fistulas in Crohn's disease |
|
|
| Completed | 4 | 126 | Europe | Infliximab, Adalimumab, LO4AB02, L04AB04, Powder for concentrate for solution for infusion, Remicade, Humira | Academic Medical Center, ACADEMIC MEDICAL CENTER, Academic Medical Center, ACADEMIC MEDICAL CENTER | Perianal fistulas in Crohn's Disease, Perianal fistulas in Crohn's Disease, Diseases [C] - Digestive System Diseases [C06] | | | | |
| Completed | 4 | 100 | Canada | Adalimumab, Humira, Capsule endoscopy, EndoCapsule EC-1, OLYMPUS EC TYPE 1 | Innovaderm Research Inc., Abbott | Plaque Psoriasis, Crohn's Disease | 01/16 | 04/16 | | |
2016-000235-40: Stopping anti-TNF treatment in Crohn’s and Colitis patients in remission Utsättning av anti-TNF terapi hos patienter med ulcerös kolit eller Crohns sjukdom i lugn fas |
|
|
| Ongoing | 4 | 350 | Europe | Concentrate and solvent for solution for infusion, Solution for injection in pre-filled pen, Remicade, Remsima, Inflectra, Humira | Region Skåne, ALF-medel | Crohn´s disease Ulcerative colitis, Crohn´s disease Ulcerative colitis Crohns sjukdom Ulcerös kolit, Diseases [C] - Digestive System Diseases [C06] | | | | |
| Completed | 4 | 100 | NA | adalimumab, Humira, ABT-D2E7 | AbbVie, Laboratorio Echevarne, Pivotal S.L. | Moderate to Severe Crohn's Disease | 08/16 | 01/17 | | |
| Completed | 4 | 97 | US | Adalimumab (Humira), Placebo Injection, NB-UVB phototherapy | University of Pennsylvania | Psoriasis, Cardiovascular Disease | 08/16 | 10/16 | | |
| Completed | 4 | 81 | US | Adalimumab, Humira | University of Pennsylvania, AbbVie | Psoriasis, Cardiovascular Disease | 08/16 | 10/16 | | |
2016-003129-40: Remission after suspension of TNF alpha therapies in RA Remissione dopo terapia con farmaci Anti TNF in pazienti affetti da Artrite Reumatoide |
|
|
| Completed | 4 | 60 | Europe | HUMIRA (ADALIMUMAB), CIMZIA (Certolizumab Pegol), ENBREL (Etanercept), REMICADE (INFLIXIMAB), SIMPONI (GOLIMUMAB), [NA], [-], Solution for injection, Powder and solvent for solution for injection, Powder for solution for injection, HUMIRA - 40 MG SOLUZIONE INIETTABILE USO SOTTOCUTANEO 2 SIRINGHE PRERIEMPITE 0.8 ML + 2 TAMPONI IMBEVUTI DI ALCOL IN 1 BLISTER, CIMZIA - 200MG-SOLUZIONE INIETTABILE-USO SOTTOCUTANEO-SIRINGA PRERIEMPITA(VETRO) 1ML 6(3X2) SIRINGHE PRERIEMPITE+6(3X2) SALVIETTINE IMBEVUTE DI ALCOOL, ENBREL - 50 MG POLV SOLUZ INIET SOTTOC. POLV. FLAC VETRO SOLV. SIRI. VET. SOLV 1 ML (50 MG/ML) 12 FLAC+12 SIRI. PRE+12 AGHI+12 ADAT PER FLAC+24 TAMP. PRE INIEZ, REMICADE - 100 MG POLVERE PER CONCENTRATO PER INFUSIONE ENDOVENOSA 1 FLACONE VETRO 20 ML USO EV, SIMPONI - 50 MG-SOLUZIONE PER INIEZIONE IN PENNA PRERIEMPITA-USO SOTTOCUTANEO-PENNA PRERIEMPITA(VETRO) -0.5 ML 3 (3X1) PENNE PRERIEMPITE | AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA, AIFA - Italian Medicines Agency | RHEUMATOID ARTHRITIS (RA) PATIENTS PAZIENTI AFFETTI DA ARTRITE REUMATOIDE (AR), RHEUMATOID ARTHRITIS (RA) PATIENTS PAZIENTI AFFETTI DA ARTRITE REUMATOIDE (AR), Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
| Completed | 4 | 251 | Europe | adalimumab, plus prednisone, humira (adalimumab), deltacortene (prednisone), adalimumab plus placebo | IRCCS Policlinico S. Matteo | Rheumatoid Arthritis | 03/17 | 03/17 | | |
NCT01893996: Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease |
|
|
| Completed | 4 | 63 | US | Adalimumab, Humira, Placebo | Jonathan Graf, American College of Rheumatology Research and Education Foundation, AbbVie | Rheumatoid Arthritis, Cardiovascular Disease | 07/17 | 07/17 | | |
| Completed | 4 | 60 | Europe | Adalimumab, Humira | Hamed Rezaei, Abbott | Rheumatoid Arthritis | 09/17 | 09/17 | | |
NCT02451748: IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA |
|
|
| Completed | 4 | 32 | US | Lab Work, Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg), Certolizumab pegol, Certolizumab pegol (CDP870, tradename Cimzia), Hydroxychloroquine, Sulfasalazine, Medrol, Prednisone, Triamcinolone, Naproxen, Leflunomide, Methotrexate, humira | University of Illinois at Chicago, UCB Pharma | Rheumatoid Arthritis | 09/17 | 12/17 | | |
2014-003022-40: Comparison of the microorganism in the skin and gut of psoriasis patients before and after different treatments Vergleichende Untersuchung von Mikroorganismen auf der Haut und im Darm von Patienten mit Schuppenflechte nach unterschiedlichen Behandlungen |
|
|
| Completed | 4 | 36 | Europe | Solution for injection in pre-filled syringe, Capsule, soft, Solution for injection in pre-filled pen, Stelara ® 45 mg Injektionslösung in einer Fertigspritze, Humira ® 40 mg Injektionslösung in Fertigspritze, Stelara ® 90 mg Injektionslösung in einer Fertigspritze, Humira ® 40 mg Injektionslösung im vorgefüllten Pen | Universitätsklinikum Münster, Janssen-Cilag GmbH | Psoriasis Schuppenflechte, Psoriasis Schuppenflechte, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
| Completed | 4 | 183 | Europe | Adalimumab, Humira | University of Leeds, AbbVie, Theorem | Rheumatoid Arthritis, Targeted Ultrasound | 12/17 | 07/19 | | |
| Unknown status | 4 | 60 | Europe | Adalimumab, PET/CT imaging | University of Helsinki, AbbVie | Ankylosing Spondyloarthritis | 12/17 | 12/17 | | |
| Terminated | 4 | 22 | NA | Adalimumab, Humira, ABT-D2E7, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Routine practice | AbbVie, IST GmbH, Germany, Hannover Medical School, Improvement by Movement GmbH, Germany | Axial Spondyloarthritis | 12/17 | 12/17 | | |
MAZERATI, NCT02353780: Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept |
|
|
| Terminated | 4 | 10 | US | TNF Antagonist (enbrel, humire, remicade, cimzia, symponi), Enbrel, Humira, Remicade, Cimzia, Symponi, Abatacept, Orencia, Tocilizumab, Actemra | Dr. Larry W. Moreland, Genentech, Inc., Bristol-Myers Squibb | Rheumatoid Arthritis (RA) | 12/17 | 11/18 | | |
